Does the media refer more to AVTX or FATE?

In the previous week, Fate Therapeutics had 1 more articles in the media than Avalo Therapeutics. MarketBeat recorded 3 mentions for Fate Therapeutics and 2 mentions for Avalo Therapeutics. Fate Therapeutics' average media sentiment score of 1.78 beat Avalo Therapeutics' score of 0.94 indicating that Fate Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fate Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to JANX or FATE?

In the previous week, Janux Therapeutics had 6 more articles in the media than Fate Therapeutics. MarketBeat recorded 9 mentions for Janux Therapeutics and 3 mentions for Fate Therapeutics. Fate Therapeutics' average media sentiment score of 1.78 beat Janux Therapeutics' score of 1.38 indicating that Fate Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fate Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor FATE or KURA?

In the previous week, Kura Oncology had 21 more articles in the media than Fate Therapeutics. MarketBeat recorded 24 mentions for Kura Oncology and 3 mentions for Fate Therapeutics. Fate Therapeutics' average media sentiment score of 1.78 beat Kura Oncology's score of 0.75 indicating that Fate Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fate Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Kura Oncology 10 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend CVAC or FATE?

Fate Therapeutics has a consensus price target of $5.90, suggesting a potential upside of 142.80%. Given Fate Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Fate Therapeutics is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Fate Therapeutics 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.38

Which has preferable earnings & valuation, CVAC or FATE?

CureVac has higher revenue and earnings than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CureVac $70.74M 14.78 $175.50M $0.72 6.47 Fate Therapeutics $6.65M 43.78 -$136.32M -$1.05 N/A

Fate Therapeutics (FATE) Competitors

$2.43 -0.11 (-4.33%)

As of 08/28/2026 04:00 PM Eastern

Compare

FATE vs. AVTX, JANX, KURA, CVAC, and WVE

Should you buy Fate Therapeutics stock or one of its competitors? Fate Therapeutics's main competitors and comparable companies include Avalo Therapeutics (AVTX), Janux Therapeutics (JANX), Kura Oncology (KURA), CureVac (CVAC), and WAVE Life Sciences (WVE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Fate Therapeutics compare to Avalo Therapeutics?

Avalo Therapeutics (NASDAQ:AVTX) and Fate Therapeutics (NASDAQ:FATE) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Avalo Therapeutics currently has a consensus target price of $45.10, indicating a potential upside of 130.22%. Fate Therapeutics has a consensus target price of $5.90, indicating a potential upside of 142.80%. Given Fate Therapeutics' higher probable upside, analysts clearly believe Fate Therapeutics is more favorable than Avalo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are owned by institutional investors. 4.5% of Avalo Therapeutics shares are owned by insiders. Comparatively, 4.7% of Fate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Fate Therapeutics had 1 more articles in the media than Avalo Therapeutics. MarketBeat recorded 3 mentions for Fate Therapeutics and 2 mentions for Avalo Therapeutics. Fate Therapeutics' average media sentiment score of 1.78 beat Avalo Therapeutics' score of 0.94 indicating that Fate Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fate Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Avalo Therapeutics has higher earnings, but lower revenue than Fate Therapeutics. Avalo Therapeutics is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$59K	17,806.98	-$78.26M	-$4.37	N/A
Fate Therapeutics	$6.65M	43.78	-$136.32M	-$1.05	N/A

Avalo Therapeutics has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market. Comparatively, Fate Therapeutics has a beta of 2.52, indicating that its stock price is 152% more volatile than the broader market.

Avalo Therapeutics has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,941.09%. Avalo Therapeutics' return on equity of -58.03% beat Fate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-58.03%	-48.22%
Fate Therapeutics	-1,941.09%	-65.08%	-41.73%

Summary

Fate Therapeutics beats Avalo Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Fate Therapeutics compare to Janux Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and Fate Therapeutics (NASDAQ:FATE) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, media sentiment, earnings, dividends and profitability.

Janux Therapeutics has higher revenue and earnings than Fate Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$10M	110.24	-$113.62M	-$1.64	N/A
Fate Therapeutics	$6.65M	43.78	-$136.32M	-$1.05	N/A

In the previous week, Janux Therapeutics had 6 more articles in the media than Fate Therapeutics. MarketBeat recorded 9 mentions for Janux Therapeutics and 3 mentions for Fate Therapeutics. Fate Therapeutics' average media sentiment score of 1.78 beat Janux Therapeutics' score of 1.38 indicating that Fate Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Janux Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fate Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Janux Therapeutics has a beta of 2.5, indicating that its share price is 150% more volatile than the broader market. Comparatively, Fate Therapeutics has a beta of 2.52, indicating that its share price is 152% more volatile than the broader market.

Janux Therapeutics presently has a consensus target price of $36.46, suggesting a potential upside of 102.23%. Fate Therapeutics has a consensus target price of $5.90, suggesting a potential upside of 142.80%. Given Fate Therapeutics' higher probable upside, analysts clearly believe Fate Therapeutics is more favorable than Janux Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

75.4% of Janux Therapeutics shares are held by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are held by institutional investors. 7.9% of Janux Therapeutics shares are held by insiders. Comparatively, 4.7% of Fate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Janux Therapeutics has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,941.09%. Janux Therapeutics' return on equity of -11.89% beat Fate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-11.89%	-11.13%
Fate Therapeutics	-1,941.09%	-65.08%	-41.73%

Summary

Janux Therapeutics beats Fate Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Fate Therapeutics compare to Kura Oncology?

Fate Therapeutics (NASDAQ:FATE) and Kura Oncology (NASDAQ:KURA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Fate Therapeutics currently has a consensus target price of $5.90, indicating a potential upside of 142.80%. Kura Oncology has a consensus target price of $25.40, indicating a potential upside of 100.63%. Given Fate Therapeutics' higher probable upside, research analysts plainly believe Fate Therapeutics is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Kura Oncology has a net margin of -384.30% compared to Fate Therapeutics' net margin of -1,941.09%. Fate Therapeutics' return on equity of -65.08% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fate Therapeutics	-1,941.09%	-65.08%	-41.73%
Kura Oncology	-384.30%	-207.18%	-45.17%

97.5% of Fate Therapeutics shares are held by institutional investors. 4.7% of Fate Therapeutics shares are held by company insiders. Comparatively, 7.6% of Kura Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Fate Therapeutics has higher earnings, but lower revenue than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fate Therapeutics	$6.65M	43.78	-$136.32M	-$1.05	N/A
Kura Oncology	$67.48M	16.69	-$278.67M	-$3.37	N/A

In the previous week, Kura Oncology had 21 more articles in the media than Fate Therapeutics. MarketBeat recorded 24 mentions for Kura Oncology and 3 mentions for Fate Therapeutics. Fate Therapeutics' average media sentiment score of 1.78 beat Kura Oncology's score of 0.75 indicating that Fate Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fate Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Kura Oncology	10 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Fate Therapeutics has a beta of 2.52, meaning that its share price is 152% more volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market.

Summary

Fate Therapeutics beats Kura Oncology on 10 of the 16 factors compared between the two stocks.

How does Fate Therapeutics compare to CureVac?

CureVac (NASDAQ:CVAC) and Fate Therapeutics (NASDAQ:FATE) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

CureVac has a net margin of 199.92% compared to Fate Therapeutics' net margin of -1,941.09%. CureVac's return on equity of -23.03% beat Fate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Fate Therapeutics	-1,941.09%	-65.08%	-41.73%

CureVac has higher revenue and earnings than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Fate Therapeutics	$6.65M	43.78	-$136.32M	-$1.05	N/A

CureVac has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market. Comparatively, Fate Therapeutics has a beta of 2.52, meaning that its stock price is 152% more volatile than the broader market.

17.3% of CureVac shares are owned by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are owned by institutional investors. 2.2% of CureVac shares are owned by company insiders. Comparatively, 4.7% of Fate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Fate Therapeutics had 3 more articles in the media than CureVac. MarketBeat recorded 3 mentions for Fate Therapeutics and 0 mentions for CureVac. Fate Therapeutics' average media sentiment score of 1.78 beat CureVac's score of 0.00 indicating that Fate Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
CureVac	Neutral
Fate Therapeutics	Very Positive

Fate Therapeutics has a consensus price target of $5.90, suggesting a potential upside of 142.80%. Given Fate Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Fate Therapeutics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

Summary

Fate Therapeutics beats CureVac on 9 of the 16 factors compared between the two stocks.

How does Fate Therapeutics compare to WAVE Life Sciences?

Fate Therapeutics (NASDAQ:FATE) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

97.5% of Fate Therapeutics shares are held by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are held by institutional investors. 4.7% of Fate Therapeutics shares are held by company insiders. Comparatively, 24.3% of WAVE Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Fate Therapeutics had 2 more articles in the media than WAVE Life Sciences. MarketBeat recorded 3 mentions for Fate Therapeutics and 1 mentions for WAVE Life Sciences. WAVE Life Sciences' average media sentiment score of 1.87 beat Fate Therapeutics' score of 1.78 indicating that WAVE Life Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Fate Therapeutics	Very Positive
WAVE Life Sciences	Very Positive

Fate Therapeutics has higher earnings, but lower revenue than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fate Therapeutics	$6.65M	43.78	-$136.32M	-$1.05	N/A
WAVE Life Sciences	$42.73M	23.24	-$204.38M	-$1.09	N/A

Fate Therapeutics currently has a consensus target price of $5.90, suggesting a potential upside of 142.80%. WAVE Life Sciences has a consensus target price of $22.53, suggesting a potential upside of 347.01%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe WAVE Life Sciences is more favorable than Fate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
WAVE Life Sciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

WAVE Life Sciences has a net margin of -309.73% compared to Fate Therapeutics' net margin of -1,941.09%. WAVE Life Sciences' return on equity of -50.36% beat Fate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fate Therapeutics	-1,941.09%	-65.08%	-41.73%
WAVE Life Sciences	-309.73%	-50.36%	-40.06%

Fate Therapeutics has a beta of 2.52, suggesting that its stock price is 152% more volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.26, suggesting that its stock price is 226% less volatile than the broader market.

Summary

WAVE Life Sciences beats Fate Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Fate Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FATE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FATE vs. The Competition

Export

Metric	Fate Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$291.16M	$3.93B	$7.21B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-2.31	11.62	273.16	25.42
Price / Sales	43.78	1,371.16	629.76	95.09
Price / Cash	N/A	44.06	28.74	36.03
Price / Book	1.35	16.92	11.08	6.36
Net Income	-$136.32M	-$22.74M	$3.48B	$349.79M
7 Day Performance	4.29%	-0.31%	0.13%	-0.80%
1 Month Performance	-3.19%	9.80%	7.08%	4.13%
1 Year Performance	133.65%	55.66%	24.67%	15.17%

Fate Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FATE Fate Therapeutics	3.1608 of 5 stars	$2.43 -4.3%	$5.90 +142.8%	+133.7%	$291.16M	$6.65M	N/A	550	Positive News
AVTX Avalo Therapeutics	2.8453 of 5 stars	$19.27 -2.8%	$45.10 +134.0%	+110.9%	$1.06B	$59K	N/A	40
JANX Janux Therapeutics	2.8722 of 5 stars	$18.60 +7.0%	$36.46 +96.0%	-20.6%	$1.06B	$24M	N/A	30	News Coverage Gap Up High Trading Volume
KURA Kura Oncology	3.9153 of 5 stars	$12.40 +4.3%	$25.40 +104.8%	+60.3%	$1.06B	$67.48M	N/A	130
CVAC CureVac	N/A	$4.66 flat	N/A	N/A	$1.05B	$70.74M	6.47	880

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FATE) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fate Therapeutics (FATE) Competitors

FATE vs. AVTX, JANX, KURA, CVAC, and WVE

How does Fate Therapeutics compare to Avalo Therapeutics?

Summary

How does Fate Therapeutics compare to Janux Therapeutics?

Summary

How does Fate Therapeutics compare to Kura Oncology?

Summary

How does Fate Therapeutics compare to CureVac?

Summary

How does Fate Therapeutics compare to WAVE Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FATE vs. The Competition

Fate Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fate Therapeutics (FATE) Competitors

FATE vs. AVTX, JANX, KURA, CVAC, and WVE

How does Fate Therapeutics compare to Avalo Therapeutics?

Do analysts recommend AVTX or FATE?

Do institutionals and insiders have more ownership in AVTX or FATE?

Does the media refer more to AVTX or FATE?

Which has stronger valuation & earnings, AVTX or FATE?

Which has more volatility and risk, AVTX or FATE?

Is AVTX or FATE more profitable?

Summary

How does Fate Therapeutics compare to Janux Therapeutics?

Which has better valuation & earnings, JANX or FATE?

Does the media refer more to JANX or FATE?

Which has more volatility & risk, JANX or FATE?

Do analysts recommend JANX or FATE?

Do insiders & institutionals believe in JANX or FATE?

Is JANX or FATE more profitable?

Summary

How does Fate Therapeutics compare to Kura Oncology?

Do analysts recommend FATE or KURA?

Is FATE or KURA more profitable?

Do insiders and institutionals have more ownership in FATE or KURA?

Which has better earnings & valuation, FATE or KURA?

Does the media favor FATE or KURA?

Which has more volatility and risk, FATE or KURA?

Summary

How does Fate Therapeutics compare to CureVac?

Is CVAC or FATE more profitable?

Which has preferable earnings & valuation, CVAC or FATE?

Which has more volatility & risk, CVAC or FATE?

Do institutionals and insiders hold more shares of CVAC or FATE?

Does the media favor CVAC or FATE?

Do analysts recommend CVAC or FATE?

Summary

How does Fate Therapeutics compare to WAVE Life Sciences?

Do insiders & institutionals hold more shares of FATE or WVE?

Does the media prefer FATE or WVE?

Which has stronger valuation & earnings, FATE or WVE?

Do analysts prefer FATE or WVE?

Is FATE or WVE more profitable?

Which has more volatility & risk, FATE or WVE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FATE vs. The Competition

Fate Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools